WATERTOWN, Mass.--(BUSINESS WIRE)--Jun. 23, 2020--
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the closing of its initial public offering of 15,964,704 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 2,082,352 additional shares of common stock, at a public offering price of $20.00 per share. The aggregate gross proceeds to Forma from the offering were approximately $319.3 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Forma.
Jefferies, SVB Leerink and Credit Suisse acted as joint book-running managers for the offering.
Registration statements relating to these securities have been filed with the Securities and Exchange Commission (“SEC”) and became effective on June 18, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@Jefferies.com; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6218, or by email at email@example.com; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200623005840/en/
Kari Watson, +1 781-235-3060
Stephanie Ascher, +1 212-362-1200
Stern Investor Relations
Source: Forma Therapeutics Holdings, Inc